Notable Mover: Can Heron Therapeutics Inc’s Tomorrow be Different? The Stock Just Broke Its 1 Year Low

Notable Mover: Can Heron Therapeutics Inc's Tomorrow be Different? The Stock Just Broke Its 1 Year Low

The stock of Heron Therapeutics Inc (NASDAQ:HRTX) hit a new 52-week low and has $14.83 target or 6.00% below today’s $15.78 share price. The 7 months bearish chart indicates high risk for the $621.10 million company. The 1-year low was reported on Oct, 3 by Barchart.com. If the $14.83 price target is reached, the company will be worth $37.27M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 552,173 shares traded hands or 5.68% up from the average. Heron Therapeutics Inc (NASDAQ:HRTX) has risen 8.50% since February 29, 2016 and is uptrending. It has underperformed by 3.71% the S&P500.

Analysts await Heron Therapeutics Inc (NASDAQ:HRTX) to report earnings on November, 4. They expect $-1.11 earnings per share, down 76.19% or $0.48 from last year’s $-0.63 per share. After $-1.17 actual earnings per share reported by Heron Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.13% EPS growth.

Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage

Out of 6 analysts covering Heron Therapeutics (NASDAQ:HRTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics has been the topic of 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Brean Capital maintained it with “Buy” rating and $45 target price in Monday, August 3 report. As per Wednesday, September 23, the company rating was maintained by Jefferies. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) has “Buy” rating given on Thursday, December 10 by Lake Street. The firm has “Outperform” rating by Leerink Swann given on Wednesday, September 23. The rating was initiated by Bank of America on Wednesday, September 2 with “Buy”. The rating was maintained by Brean Capital on Monday, August 10 with “Buy”.

According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.”

More notable recent Heron Therapeutics Inc (NASDAQ:HRTX) news were published by: Seekingalpha.com which released: “Three execs out at Heron Therapeutics” on October 03, 2016, also Fool.com with their article: “Here’s Why Heron Therapeutics, Inc. Stock Gained 25% Today” published on September 23, 2015, Seekingalpha.com published: “Heron Therapeutics Has An Upcoming Approval” on July 18, 2016. More interesting news about Heron Therapeutics Inc (NASDAQ:HRTX) were released by: Wsj.com and their article: “FDA Approves Heron Therapeutics Anti-nausea Drug Sustol” published on August 10, 2016 as well as Marketwatch.com‘s news article titled: “Heron Therapeutics shares rise 18% in pre-market trade after company said …” with publication date: August 10, 2016.

HRTX Company Profile

Heron Therapeutics, Inc., incorporated on February 5, 1987, is a biotechnology company. The Firm is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment